scPharmaceuticals Inc. (SCPH): Price and Financial Metrics


scPharmaceuticals Inc. (SCPH): $5.41

0.02 (+0.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SCPH Stock Price Chart Interactive Chart >

Price chart for SCPH

SCPH Price/Volume Stats

Current price $5.41 52-week high $9.64
Prev. close $5.39 52-week low $5.06
Day low $5.12 Volume 67,074
Day high $5.56 Avg. volume 84,495
50-day MA $6.05 Dividend yield N/A
200-day MA $7.04 Market Cap 147.99M

scPharmaceuticals Inc. (SCPH) Company Bio


scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.


SCPH Latest News Stream


Event/Time News Detail
Loading, please wait...

SCPH Latest Social Stream


Loading social stream, please wait...

View Full SCPH Social Stream

Latest SCPH News From Around the Web

Below are the latest news stories about scPharmaceuticals Inc that investors may wish to consider to help them evaluate SCPH as an investment opportunity.

scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. Business Update Conducted a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the FUROSCIX® New Drug Application (NDA) and requirements related to its resubmission.The Company is still in discussion with the FDA regarding the...

Yahoo | May 12, 2021

scPharmaceuticals to Present in Two Upcoming Investor Conferences

BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate in two upcoming investor conferences. Event: Cowen 41st Annual Healthcare ConferenceThursday, March 410:30am EDT H.C. Wainwright Global Life Sciences ConferenceTuesday, March 9 – Wednesday, March 10 A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am ET, Tuesday, March 9 A live webcast of both presentations can be accessed under “News & Events” in the Investor Relations section of the Compan...

Yahoo | February 25, 2021

What Is The Ownership Structure Like For scPharmaceuticals Inc. (NASDAQ:SCPH)?

Every investor in scPharmaceuticals Inc. ( NASDAQ:SCPH ) should be aware of the most powerful shareholder groups. Large...

Yahoo | February 24, 2021

ScPharmaceuticals Sees US Application Submission For Furoscix In Q3

ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional clinical studies to demonstrate the safety and efficacy of Furoscix. In December last year, the company received a Complete Response Letter due to the FDA's inability to conduct pre-approval inspections at two of scPharma's third-party manufacturing facilities due to travel restrictions. The letter also cited concerns regarding testing, labeling, and features of the combination product unrelated to the drug constituent, as well as deficiencies at the third-party facility where the company's off-the-shelf alcohol swabs are manufactured. The company still anticipates the need for inspections o...

Yahoo | February 23, 2021

scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors

BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of William T. Abraham, M.D., to the company’s Board of Directors. Dr. Abraham currently serves as Professor of Internal Medicine (Cardiology), Physiology and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University as well as Chief Medical Officer at V-Wave Ltd., a privately held developer of percutaneous implantable therapeutic devices for chronic heart failure patients. “I could not be more excited to welcome Dr. Abraham to our Board. H...

Yahoo | February 17, 2021

Read More 'SCPH' Stories Here

SCPH Price Returns

1-mo -8.15%
3-mo -23.91%
6-mo -6.56%
1-year -30.01%
3-year -2.17%
5-year N/A
YTD 2.27%
2020 -6.54%
2019 50.53%
2018 -68.90%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8139 seconds.